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Psychoactive “bath salts” represent a continuing drug abuse problem. The synthetic
cathinones, 3, 4-methylenedioxypyrovalerone (MDPV) and 4-methylmethcathinone (4-MMC)
are popular constituents of “bath salts” in the United States and the United Kingdom,
respectively. Addiction to these substances has proven difficult to treat, possibly requiring
targeted therapeutics. Drug discrimination is a preclinical assay that may aid in treatment
development. Thus far, two-lever (drug vs no drug) discrimination studies have exhibited
asymmetrical substitution patterns between 4-MMC and MDPV. Therefore, a three-lever
discrimination method was employed in which 12 male Sprague-Dawley rats were trained to
discriminate 0.5 mg/kg MDPV, 2.0 mg/kg 4-MMC, and saline vehicle. The discrimination was
established within 39.8(± 3.9 S. E. M.) training sessions. Both MDPV and 4-MMC produced
excellent stimulus control and dose-dependent increases in responding on the conditionappropriate lever. Response rate remained relatively stable across training and test sessions
although was slightly higher under saline conditions. The present results indicate that 4-MMC
and MDPV may produce substantially different subjective effects. Serotonergic mechanisms
may contribute to these differential effects, but further experimentation is needed. The present
data support a body of evidence that the three-lever drug discrimination design may be more
sensitive to detecting differences between pharmacologically related substances.

ACKNOWLEDGEMENTS
Without the help of those surrounding me, the completion of this thesis would not have
been possible. I would first like to thank my family including my mother and father, Donna and
Norman Bullock, and my brother and sister, Kori and Kyle Bullock. Without their support
throughout my master’s program, it would have been easy to lose sight of my end goal. I would
like to thank my Grandmother, Betty Bullock, whose interest in my work keeps me going even
when the experiments get tedious. Also deserving of thanks are my grandparents, Guy Bullock
and Madge Price. Although they have passed, they played a crucial role in developing my values
and teaching me to always persevere.
Second, I want to thank those who aided and advised me through my master’s program.
To Dr. Lisa Baker, I owe my gratitude for her patience and guidance. To my lab mates, Harmony
Risca, Doug Smith, Bob Kohler, Rachel Burroughs, and Luke Price, it was a pleasure to work
with you all, and I thank you for your advice and assistance during this project. I am especially
indebted to Angela Goolsby without whose assistance in running training sessions, I may not
have completed this project. Lastly, I want to thank the additional members of my thesis
committee, Dr. Alan Poling and Dr. Cynthia Pietras from whom I have learned a great deal about
behavior and its corresponding science.

Trent A. Bullock

ii

TABLE OF CONTENTS
ACKNOWLEDGEMENTS ............................................................................................. ii
LIST OF TABLES ........................................................................................................... v
LIST OF FIGURES ......................................................................................................... vi
CHAPTER
I.

INTRODUCTION .................................................................................... 1
Substance Abuse ................................................................................. 1
Synthetic Cathinones ........................................................................... 2
3, 4-methylenedioxypyrovalerone ........................................................ 4
4-methylmethcathinone ........................................................................ 6
Drug Discrimination and Study Rationale ............................................ 7

II.

EXPERIMENTAL METHODS ................................................................. 10
Animal Subjects.................................................................................. 10
Apparatus ........................................................................................... 10
Drugs .................................................................................................. 11
Operant Training Procedures .............................................................. 11
Magazine Training .............................................................. 11
Preliminary Training ........................................................... 11
Discrimination Training ...................................................... 12
Substitution Tests................................................................ 13
Data Analysis ..................................................................................... 14

III.

RESULTS.................................................................................................. 15
Discrimination Acquisition ................................................................. 15

iii

Table of Contents—Continued
CHAPTER
Substitution Tests ............................................................................... 16
IV.

DISCUSSION............................................................................................ 19

REFERENCES...................................................................................................... 23
APPENDIX ........................................................................................................... 28

iv

LIST OF TABLES
1. Compounds for Substitution Tests ........................................................................ 13

v

LIST OF FIGURES
1. Discrimination Acquisition ................................................................................... 15
2. Response Rate During Discrimination Training .................................................... 16
3. 4-MMC and MDPV Dose Response Curves ......................................................... 17

vi

1
CHAPTER I
INTRODUCTION
Substance Abuse
Substance Use Disorder (SUD) is an ongoing public health concern that requires
continuous research efforts to develop new treatments and therapies. According to the
Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM-5), SUD is characterized
by persistent behavioral, physical, social, and psychological impairments as they pertain to the
use of drugs and/or alcohol (American Psychiatric Association, 2013). The DSM-5 categorizes
SUD into six subtypes: alcohol, tobacco, cannabis, stimulant, hallucinogen, and opioid, and it
encourages determining the severity of a SUD along a continuum, ranging from mild to severe
(APA, 2013; Substance Abuse and Mental Health Services Administration, 2014).
A National Drug Threat Assessment published by the Drug Enforcement Agency (DEA)
of the United States Department of Justice (USDOJ) states that deaths due to drug poisoning are
at their highest rates ever (2016). At nearly 50,000 deaths in 2014 alone, drug poisoning
outnumbers deaths due to suicide, homicide, motor vehicle accidents, and firearm related
incidents (DEA, 2016). Reports from the Centers for Disease Control and Prevention (CDC)
estimate drug overdose deaths at around 52,000 for 2015 and 64,000 for 2016 (Seth, Scholl,
Rudd, & Bacon, 2018). Although opioid and heroin overdoses account for the largest portion of
deaths (42,000 in 2016) and synthetic opioid overdoses represented the greatest increase in death
rate (100% increase between 2015 and 2016), the rate of overdose deaths related to cocaine and
other psychostimulants also increased 52.4% and 33.3%, respectively (Seth et al., 2018).
Exacerbating the problem are reports that illicit drug use costs the American economy
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approximately $193 billion between costs related to crime, healthcare, and lost productivity
(USDOJ, 2011).
Synthetic Cathinones
Synthetic cathinones are psychomotor stimulants derived from cathinone, the active
ingredient in the Catha edulis (khat) plant. Classified by the DEA (2016) as one of the two major
classes of New Psychoactive Substances (NPS), synthetic cathinones provided the blueprint for
how to circumvent laws, such as the Controlled Substances Act of 1970, and began a trend of
“legal highs.” Initially, synthetic cathinones were marketed as “bath salts,” “research chemicals,”
“plant food,” or simply “not for human consumption” in an effort to avoid detection by
authorities (DEA, 2016; German, Fleckenstein, and Hanson, 2014). The DEA now states that this
form of marketing for synthetic cathinones is subsiding in favor of names such as “Molly.” This
name is presumed to suggest that buyers are getting a pure form of another drug, 3, 4methylenedioxymethamphetamine (MDMA). However, synthetic cathinones are common in
drug formulations sold under the aforementioned street names (DEA, 2016). In general, “legal
highs” may contain little of the active ingredient advertised on their labels, or the advertised
active ingredient may be mixed with other substances (Baron, Elie, and Elie, 2011).
Several recent longitudinal studies monitoring drug use trends indicate that the use of
synthetic cathinones is stable, if not declining (Johnston, Miech, O’Malley, Bachman,
Schulenberg, and Patrick, 2018; European Monitoring Center for Drugs and Drug Addiction
(EMCDDA), 2017). The DEA (2016) also notes that calls to poison control centers regarding
synthetic cathinones toxicity peaked in 2011 and have declined every year since. However,
several factors may be artificially deflating these numbers. Notably, the DEA (2016) suggests
that emergency departments are now more familiar with the toxidrome associated with synthetic
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cathinones. Thus, they may be able to treat overdoses better without the need to call poison
control centers. More concerning, the new marketing strategies for synthetic cathinones may be
confusing drug users into thinking they are consuming a different drug when they are in fact
using a synthetic cathinone formulation (DEA, 2016).
As b-ketone analogues to the schedule II-controlled substance amphetamine, synthetic
cathinones are similar structurally and pharmacologically to both amphetamine and related
compounds like MDMA (Banks, Worst, and Sprague, 2014; for review, see Coppola and
Mondola, 2012). For example, the popular synthetic cathinone constituent, 3,
4-methylenedioxypyrovalerone (MDPV), is a potent blocker of catecholamine transporters, such
as the dopamine and norepinephrine transporters (DAT and NET, respectively), and it is
significantly less potent as a blocker of the serotonin (5-HT) transporter (SERT) (Baumann et al.,
2013). Conversely, another popular synthetic cathinone constituent, 4-methylmethcathinone
(mephedrone, 4-MMC), functions as a substrate for monoamine transporters and is nearly
equipotent at DAT, NET, and SERT (Baumann et al., 2012). Cameron, Kolanos, Solis, Glennon,
and De Felice (2013a) and Cameron, Kolanos, Verkariya, De Felice, and Glennon (2013b)
demonstrated the potency of MDPV as a dopamine reuptake inhibitor via human DAT inhibition
whereas 4-MMC seemed to function as a dopamine releaser at hDAT. Although there are clear
differences in mechanistic actions, the selectivity of MDPV to increase extracellular
catecholamine concentrations is similar to that of amphetamine, cocaine, and methamphetamine
(Baumann et al., 2013; Cameron et al., 2013a; Cameron et al., 2013b). Likewise, the relative
non-selectivity of 4-MMC to increase extracellular concentrations of monoamines is similar to
that of MDMA (Cameron et al., 2013a; Cameron et al., 2013b; Baumann et al., 2012).
Considering these subtle differences in pharmacological effects, one may infer that these drugs
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have similar, though not identical physiological and behavioral effects. These effects are
examined in the following sections, with special attention paid to MDPV and 4-MMC.
3, 4-methylenedioxypyrovalerone (MDPV)
MDPV is one of the more popular synthetic cathinone constituents among drug users in
the United States (Johnson and Johnson, 2014; Shanks, Dahn, Behonick, and Terrell, 2012). As
previously mentioned, MDPV is a potent monoamine reuptake blocker with high selectivity for
DAT and NET and low selectivity for SERT (Baumann et al., 2013). User reported subjective
effects frequently associated with MDPV include feeling energetic/stimulated and a decreased
appetite (Hall, Heyd, Butler, and Yarema, 2014; Johnson and Johnson, 2014). Less frequently
reported, though still common, are feelings of increased sexual drive, euphoria, enhanced focus,
and talkativeness (Johnson and Johnson, 2014). MDPV users also reported a number of adverse
effects similar to those of other psychostimulants such as tachycardia, shortness of breath,
paranoia, and chest pain (Hall et al., 2014; Johnson and Johnson, 2014). Myocardial infarction
and death are also reported consequences of MDPV use following both binge patterns and
standard recreational use (Wright, Cline-Parhamovich, Lajoie, Parsons, Dunn, and Ferslew,
2013).
The behavioral profile of MDPV is similar to that of other abused psychostimulants.
Other than the user reported subjective effects previously mentioned, MDPV produces behaviors
similar to other psychostimulants in animal models, especially preclinical trials of abuse liability.
For example, MDPV produces locomotor sensitization following daily repeated administration
(Berquist, Traxler, Mahler, and Baker, 2016) and it produces cross-sensitization to stimulants
such as cocaine (Lopez-Arnau et al., 2017; Berquist et al., 2016). Conditioned place preference
(CPP) is induced by MDPV, sometimes with greater preference shown for MDPV-paired
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environments than environments paired with other addictive stimulants (King, Wetzell, Rice, and
Riley, 2015; King, Wakeford, Taylor, Wetzell, Rice, and Riley, 2015; Karlsson, Andersson,
Kronstrand, and Kugelberg, 2014). Adolescent exposure to MDPV also increases the rewarding
properties of stimulants such as cocaine during adulthood (Lopez-Arnau et al., 2017).
A number of self-administration studies support that MDPV has potent addictive
properties. For example, Simmons et al. (2016) demonstrated that MDPV is more readily selfadministered than cocaine. Moreover, the same study found that rat ultra-sonic vocalizations, a
measure of positive affect, were present in anticipation of the drug and persisted longer
following drug administration when compared to cocaine. Watterson et al. (2014) demonstrated
that MDPV treatment lowered the threshold for intracranial self-stimulation, a measure of drug
reinforcing properties. They also showed that longer access to MDPV produced greater drug
intake from animals. Aarde, Huang, Dickerson, and Taffe (2015) presented on the pattern of selfadministration acquisition for MDPV finding that not only did rats engage in a binge-like selfadministration pattern for this drug, but also that MDPV readily competed with natural
reinforcement, despite that the study design allowed both MDPV self-administration and natural
reinforcement. Gannon, Russell, Modi, Rice, and Fantegrossi (2017) found that mice would
orally self-administer MDPV, although MDPV preference was not greater than that for water.
Lastly, Gannon, Rice, and Collins (2017) demonstrated that both enantiomers of MDPV were
readily self-administered at rates comparable to the racemate, although the R enantiomer was
less potent than the S enantiomer. Coupled with DEA (2016) concerns regarding synthetic
cathinones and reports of potentially serious side effects (Hall et al., 2014; Johnson and Johnson,
2014), these data clearly demonstrate the potential public health threat posed by MDPV.
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4-methylmethcathinone (4-MMC, mephedrone)
Compared to MDPV, the synthetic cathinone constituent 4-MMC (also known as
mephedrone) seems to be more popular among drug users in the United Kingdom (Winstock,
Mitcheson, Ramsey, Davies, Puchnarewicz, and Marsden, 2011; Winstock, Mitcheson, Deluca,
Davey, Corazza, and Shifano, 2010). Human reports of 4-MMC subjective effects, however, are
similar to those subjective effects reported by MDPV users (Hall et al., 2014; Johnson and
Johnson, 2014; Winstock et al., 2011). Such reports may be expected considering the similar
pharmacological effects of MDPV and 4-MMC, noted previously. Like MDPV, 4-MMC use in
humans may produce a number of toxicological effects typical of psychostimulants up to and
including fatality (for review see Busardo, Kyriakou, Napoletano, Marinelli, and Zaami, 2015).
Similarities between 4-MMC and MDPV do not stop at pharmacology and subjective
effects. Preclinical abuse liability studies reveal that many behavioral effects observed when
MDPV is administered to animals also occur when 4-MMC is administered. For example,
behavioral sensitization is evident after repeated daily treatment with 4-MMC (Berquist et al.,
2016; Gregg, Tallarida, Reitz, McCurdy, and Rawls, 2013; Lisek et al., 2012) and prior treatment
with 4-MMC enhances subsequent locomotor response to other psychostimulants such as
cocaine (Berquist et al., 2016; Gregg, Tallarida, Reitz, and Rawls, 2013) and amphetamine
(Berquist, Peet, and Baker, 2015). Conditioned place preference has been established following
4-MMC treatment (Karlsson et al., 2014; Lisek et al., 2012). Lastly, a number of experiments
support that animals will readily self-administer 4-MMC (Nguyen, Grant, Creehan, Vandewater,
and Taffe, 2016; Creehan, Vandewater, and Taffe, 2015; Motbey et al., 2013). Like MDPV,
these studies provide a plethora of evidence that 4-MMC has abuse liability and could be
considered a threat to public health.
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Drug Discrimination and Study Rationale
Based on the evidence summarized above, clear similarities are noted between 4-MMC
and MDPV with regard to behavioral and pharmacological effects and their abuse liability as
predicted by preclinical assays. Nevertheless, these substances are structurally and
pharmacologically distinct. When reviewed by Glennon (2014), the concluding remarks called
for targeted therapeutic interventions for synthetic cathinones based on sometimes subtle, but
still heterogeneous, effects of these drugs at neuroreceptors and neural pathways involved in
addiction.
Drug discrimination is a preclinical assay with pharmacological specificity that may be
helpful in identifying such therapeutic interventions. Discrimination, in the behavioral sense, is
the act of differential responding to distinct stimuli. In drug discrimination, the distinct stimuli
are presumed to be the interoceptive effects associated with centrally-mediated actions of a drug.
Typically, drug discrimination is employed using two alternative responses that come under the
control of a drug stimulus through a process of differential reinforcement. Subjects receive
reinforcement for emitting a particular response (e.g., a left lever press) in the presence of a drug.
On other occasions, they receive reinforcement for making an alternative response (e.g., a right
lever press) in the absence of the drug. This is referred to as a drug - not drug (DN)
discrimination. Although less common, subjects may be trained to discriminate two different
drug stimuli, a design referred to as drug - drug (DD). Numerous researchers have investigated
4-MMC or MDPV using the former DN design (Varner et al. 2013; Gatch et al. 2013;
Fantegrossi et al., 2013; Gannon et al., 2016; Harvey and Baker, 2016; Harvey et al., 2017;
Berquist and Baker, 2017; Berquist et al., 2017). Gatch, Taylor, and Forster (2013), for example,
demonstrated that both 4-MMC and MDPV substituted for the discriminative stimulus effects of
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cocaine or methamphetamine at doses that did not disrupt responding. Similarly, Harvey,
Burroughs, and Baker (2017) observed equivalent levels of substitution by MDPV and 4-MMC
in rats trained to discriminate 0.5 mg/kg d-amphetamine. Conversely, 4-MMC substituted for
MDMA, while MDPV only produced partial substitution in rats trained to discriminate 1.5
mg/kg MDMA (Harvey and Baker, 2016). Similarly, Berquist and Baker (2017) reported that
MDMA produced minimal substitution in rats trained to discriminate 0.3 mg/kg MDPV.
Considered together, previous findings utilizing a DN discrimination suggest the
interoceptive effects of MDPV and 4-MMC are similar but not identical. Moreover, 4-MMC
appears to be more similar to MDMA. However, this may vary with species and training dose.
Fantegrossi et al. (2013) found MDMA to fully substitute in mice trained to discriminate 0.3
mg/kg MDPV. Furthermore, in DN experiments directly comparing MDPV to 4-MMC, Berquist
Thompson, and Baker (2017) found that MDPV fully substituted for a 1.0 mg/kg 4-MMC
training dose, whereas only partial substitution was observed with MDPV for a 3.0 mg/kg 4MMC training dose. In contrast MDMA fully substituted for both training doses of 4-MMC. In
rats trained to discriminate 0.3 mg/kg MDPV, Berquist and Baker (2017) reported that 4-MMC
produced only partial substitution at doses that severely disrupted responding.
Given the apparent asymmetrical substitution patterns between MDPV and 4-MMC, a
more direct comparison of 4-MMC and MDPV in the drug discrimination design is warranted.
Although a two-lever DD design could be used, some evidence suggests a three-lever
discrimination between two drugs and a not drug stimulus (DDN) may be more sensitive to
differentiating the effects of pharmacologically similar drugs. For example, Callahan and Appel
(1990) discussed the difficulties of obtaining good stimulus control between lysergic acid
diethylamide (LSD) and the pharmacologically similar substance, lisuride hydrogen maleate

9
when their laboratory used DD procedures. When a DDN procedure was attempted, however, the
pair obtained much better stimulus control, as evidenced by steep generalization gradients with
relatively little overlap in drug-lever responding. Additionally, Goodwin and Baker (2000) were
able to dissociate the discriminative stimulus effects of d-amphetamine and MDMA using DDN
procedures, although these drugs had previously exhibited asymmetrical substitution patterns,
similar to those described regarding 4-MMC and MDPV. Therefore, the major goal of the
present study was to determine if 4-MMC and MDPV cues could be established as distinct
discriminative stimuli within the same animals. Subsequent goals were to assess other related
substances for stimulus substitution to determine potential neuroreceptor targets that may
contribute to differential stimulus cues between 4-MMC and MDPV.
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CHAPTER II
EXPERIMENTAL METHODS
Animal Subjects
Twelve male Sprague-Dawley rats weighing 370-480g (Charles River Laboratories Inc.,
Kingston, NY, USA) completed the study. They were singly housed in polycarbonate cages with
corncob bedding (ENVIGO, Madison, WI, USA) in a temperature and humidity controlled
vivarium on a 12/12 light-dark cycle (lights on at 0500h). All animals had been previously used
as saline controls in conditioned place preference experiments and were approximately four
months old at the beginning of training. Animals were food restricted to maintain their weight at
approximately 85-90% of their free-feeding weight, but they had access to water in their home
cages ad libitum. Training procedures were initiated with six animals. An additional set of six
animals was added after the first six met discrimination criteria. In total, 13 animals were used
with two fatalities. The first occurred after only three sessions of discrimination training, so the
animal was replaced. The second occurred after all but one training drug substitution test had
been completed, so that animal was not replaced. All experimental procedures were in
accordance with the Guide for the Care and Use of Laboratory Animals (2013) and were
approved by the Institutional Animal Care and Use Committee of Western Michigan University.
Apparatus
All training and testing sessions were conducted in six computer-operated, standard
three-lever rat operant chambers with retractable levers (ENV-100; MED Associates, St. Albans,
VT, USA) contained within light- and sound- attenuating cabinets equipped with fans for
ventilation. At the top of the rear wall, a houselight (28V) illuminated the chambers during all
sessions. Three retractable levers were located on the front wall above a barred floor and below a
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center food magazine. The two side levers were equidistant from the center food magazine while
the center lever was located directly below the magazine. Food reinforcers consisted of 45 mg
dustless precision purified pellets for rodents (F0021, Bioserv, Frenchtown, NJ, USA). All
experimental events were recorded using Med-PC software version IV (Med-Associates, St.
Albans, VT, USA) installed on a computer running Windows XP software.
Drugs
(±) 3, 4-methylenedioxypyrovalerone hydrochloride (HCl) (MDPV) and (±) 4methylmethcathinone HCl (4-MMC) were provided by the National Institute on Drug Abuse
Drug Supply Program (Bethesda, MD, USA). Each drug solution was prepared by dissolving the
drug salt in 0.9% (wt/vol) bacteriostatic saline. All drug doses are expressed as the weight of salt.
All drug injections were performed intraperitoneally (I.P., 1 ml/kg) with a 15-minute pre-session
injection interval.
Operant Training Procedures
Magazine Training: Prior to any drug injections or lever press training, all animals were
placed in one of the operant chambers for a 60-minute time period with no levers present. During
that time, 45mg pellets were delivered on a fixed time 60-second (FT60sec) schedule to
acclimate the animals to the location of food source and sound of pellet delivery. Animals were
required to consume all of the pellets delivered during the FT60” in order to proceed to lever
press training. This was accomplished in a single one-hour session.
Preliminary Training: Lever press training sessions began following magazine training
and were conducted using errorless discrimination training procedures (i.e. only a single lever
corresponding with the pre-session injection was present). During the first session, animals
received no injection and only the center lever was present. Following the initial session, animals
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received an I.P. injection of saline vehicle, 0.5 mg/kg MDPV, or 2.0 mg/kg 4-MMC 15 minutes
prior to training and were replaced in their home cage. Following the presession interval, animals
were placed in individual operant chambers for a 20-minute training session. Drug lever
assignments were counterbalanced between the left and right levers among animals, but saline
injections always corresponded with the center lever. The training doses of MDPV and 4-MMC
were selected because those doses produced approximately equal levels of substitution for the
discriminative stimulus maintained by d-amphetamine in a previous study (Harvey et al., 2017).
Food delivery was response-dependent under a fixed-ratio (FR) schedule of
reinforcement. The animals began on a FR1 under each of the three training conditions. The FR
requirement was gradually increased from FR1 to FR20 for each condition. Ratio increases in
each condition were independent of one another. Each drug condition was presented a total of
three times during lever press training, and the saline condition was presented four times. The
order of delivery was SAL, 4-MMC, 4-MMC, SAL, MDPV, MDPV, SAL, 4-MMC, MDPV,
SAL. All animals reached FR20 under each condition without the need to extend this training
order.
Discrimination Training: During discrimination training, animals received an I.P.
injection of 4-MMC, MDPV, or saline 15 minutes prior to the beginning of the session and then
replaced in their home cages. Following the 15-minute pre-session interval, animals were placed
in individual operant chambers. All three levers were present during discrimination training.
Considering the enhanced difficulty of the three-lever discrimination task compared to
preliminary training, the FR requirement during discrimination training was lowered from a
FR20 to a FR10 schedule of reinforcement to facilitate higher levels of responding. Injection
order was pseudorandom under the stipulation that the same condition could not be presented
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more than two sessions in a row and drug conditions could not be presented more than two
sessions in a row (i.e., following two drug sessions, the next session had to be a vehicle session).
Lever assignments remained constant and were counterbalanced within groups. Criteria for
discrimination called for each animal to reach ³80% condition-appropriate responding for the
first FR and the remainder of the session for at least eight of ten consecutive discrimination
training sessions.
Substitution Tests: Substitution tests commenced once each animal reached the
aforementioned discrimination training criteria. Between testing sessions, an animal had to
complete no less than one discrimination training session on each of the three conditions wherein
the animal met the criteria of ³80% condition-appropriate responding on both the first FR and
for the entire session. If an animal’s performance fell below these criteria, discrimination training
continued until these criteria were met. Doses of test compounds were counterbalanced across
subjects. Substitution tests typically occurred one to two times per week. Test sessions were
conducted with the substances listed in Table 1:
Table 1
Compounds for Substitution Tests
Test Compound

Drug Dose (mg/kg)
4-MMC HCl
0.0, 0.25, 0.5, 1.0, 2.0, 3.0
MDPV HCl
0.0, 0.063, 0.125, 0.25, 0.5, 1.0
*Substitution tests were conducted first with 4-MMC and then with MDPV. The training dose of
4-MMC was 2.0 mg/kg and the training dose of MDPV was 0.5 mg/kg. To the best of the
experimenter’s ability, the order of test doses was counterbalanced
Test sessions were identical to discrimination training sessions in that animals were
injected I. P. with the test solution 15 minutes prior to the beginning of the session and then
replaced in their home cages. After the pre-session interval had elapsed, animals were placed into
the operant chamber and the session began. Test sessions concluded after an animal completed a
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FR10 on any lever or after 20 minutes had elapsed. Test sessions were conducted under
extinction conditions (i.e. no reinforcement followed FR completion).
Data Analysis
Response accuracy was determined by calculating the percentage of total responses
emitted on each lever prior to the delivery of the first reinforcer of each training session.
Response rate was calculated by dividing the total number of responses emitted during a training
session by 1200 seconds. Group mean (±S.E.M.) response accuracy and group mean (±S.E.M.)
response rate were plotted for each training condition over the first 55 discrimination training
sessions. Acquisition of drug stimulus control was determined by the number of discrimination
training sessions required to meet the aforementioned performance criteria. Stimulus control
acquisition was analyzed as the group mean (±S.E.M.) number of sessions required to meet
discrimination criteria.
For the analysis of substitution test results, the percentage of MDPV, 4-MMC or salinelever responses was calculated by dividing the number of responses on each lever by the total
number of responses during the test session. These data were analyzed by calculating the group
mean (±S.E.M.) percent of responses allocated to each lever following each test dose. Response
rate was recorded during each session as the number of responses emitted per second. Response
rate in drug substitution tests was analyzed by a one-way repeated measures analysis of variance
(ANOVA) followed by Tukey post-hoc comparisons.
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CHAPTER III
RESULTS
Discrimination Acquisition
The main objective of the present study was to determine if rats could learn to
discriminate the interoceptive stimulus effects of MDPV from those of 4-MMC using a threelever discrimination procedure. Response accuracy during the discrimination acquisition phase is
displayed in Figure 1, with each stimulus condition plotted separately. These data are depicted
in separate graphs for each training cohort because order of training stimulus conditions was
slightly different for the two training cohorts. However, both cohorts were combined when
determining the mean number of sessions to criterion. Briefly, stimulus control was established
under all three training conditions, with percentage of responses on the appropriate lever
gradually increasing as training progressed. The mean number of sessions to establish stimulus
control for all three conditions was 39.8 ±3.9 (S.E.M.) (Range: 22-67).
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Figure 1. Response accuracy during the discrimination acquisition phase in 12 rats (n=6 per
cohort) trained to discriminate 0.5 mg/kg MDPV, 2.0 mg/kg 4-MMC, and saline vehicle. Data
points depict the group mean (± S. E. M.) percentage of responses on each lever up until the
completion of the first FR10 during the first 55 discrimination training sessions (n=6 per cohort).
Overall response rate during the acquisition phase is plotted in Figure 2. Response rate
was relatively stable across all training conditions during the acquisition period and was slightly
higher when saline was administered than when 4-MMC or MDPV were administered. Four
animals (B2, B5, B7, and B8) were returned briefly to errorless training conditions during
discrimination training session number 18, 16, 43, and 37, respectively, because they did not
earn any reinforcers during a number of sessions.
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Figure 2. Response rate during the acquisition phase of discrimination training reported as the
group mean responses per second (± S. E. M.) for each training condition (n=6 per cohort).
Substitution Tests
Dose response curves determined from 4-MMC and MDPV substitution tests are shown
in Figure 3. During these tests, responses were allocated to the condition-appropriate lever for
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both 4-MMC and MDPV in a dose-dependent manner, whereas dose-dependent decreases in
saline-lever responses were observed. Very few responses were emitted on the MDPV lever
during 4-MMC substitution tests and vice versa.
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Figure 3. Dose response curves determined from substitution tests with 4-MMC (left) and
MDPV (right). Upper graphs depict the group mean (± S. E. M.) percentage of responses on
each lever. Lower graphs depict the group mean (± S. E. M.) response rate expressed as the total
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number of responses on any lever per second. The number of animals included in each group
mean is shown below the dose labels on the X axis in the upper graphs.
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CHAPTER IV
DISCUSSION
The specific aim of the present experiment was to determine if rats could learn to
discriminate both 4-MMC and MDPV from saline injections in a three-lever drug discrimination
procedure. To that end, this experiment was successful in that stimulus control was readily
established by these substances. Of particular interest, stimulus control was established in
approximately the same number of sessions required for rats to learn a two-lever discrimination
between either of these drugs and saline (Berquist and Baker, 2017; Berquist et al., 2017). The
speed with which stimulus control was established in the present experiment is notable because
previous three-lever discrimination studies with pharmacologically-similar drugs required nearly
twice as many sessions, on average, for stimulus control to be established (Goodwin and Baker,
2000; Callahan and Appel, 1990). Some evidence from studies with human subjects suggests that
errorless discrimination procedures produce faster learning than traditional trial and error
procedures (Schilmoeller, Schilmoeller, Etzel, and LeBlanc, 1979). Berquist et al. (2017) in part
attributed the speed with which animals learned a two-lever discrimination (4-MMC versus
saline) to errorless training procedures when comparing their results to those of Varner et al.
(2013) who used traditional trial and error training procedures. However, the errorless training
methods employed in the present three-lever discrimination were comparable to those of
Goodwin and Baker (2000) and Callahan and Appel (1990). As such, differences among these
studies in the number of sessions to obtain stimulus control are likely not due to differential
training methods.
Dose response curves with each training drug provide further support that 4-MMC and
MDPV produce differential interoceptive stimulus effects, as substitution tests with each drug
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produced virtually no responses on the other drug lever. Inasmuch as drug discrimination is a
predictive model of subjective drug effects, the current findings indicate 4-MMC and MDPV
produce substantially different subjective effects. Systematic controlled studies comparing the
subjective effects of these substances in humans are currently nonexistent. However, a random
examination of 4-MMC and MDPV user reports obtained from the website Erowid.org support
the current findings that their subjective effects are distinct. For example, details from the
accounts, Harmoniousaccord (2009), Jovialla (2010), and Smushy (2010), on the Erowid website
regarding purported 4-MMC use indicate the presence of mild to moderate hallucinogenic effects
from this drug. Two of these accounts, Harmoniousaccord and Smushy, directly compared 4MMC to MDMA. In contrast, reports from Erowid authors, GewaltHaber (2011) and
Brain_Damage (2017) regarding purported MDPV use described the effects as distinctly
different from those of MDMA. These reports also did not indicate hallucinations as an effect of
MDPV, whereas visual hallucinations seemed to be a relatively common effect reported by 4MMC user reports. It should be noted at this point, however, that Erowid user experiences are
not controlled and are categorized based on the drugs a user suspects they consumed.
The subjective effects of 4-MMC may also vary with dose. As noted in a recent report by
Berquist et al. (2017), substitution for 4-MMC with MDPV and other related compounds is
dependent on the training dose. In that study, rats trained to discriminate 1.0 mg/kg 4-MMC
generalized to MDPV and several other psychostimulants, whereas rats trained to discriminate
3.0 mg/kg 4-MMC generalized to only 4-MMC and MDMA. Therefore, the extent to which the
stimulus effects of 4-MMC and MDPV differ may depend on the particular training dose
selected. The doses selected for the current study produced equivalent levels of drug-appropriate
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responding in rats trained to discriminate d-amphetamine (Harvey et al., 2017). The fact that
these doses were discriminated readily is noteworthy.
These preliminary data indicate a role for 5-HT in the discriminative stimulus cue
mediated by 4-MMC, as serotonergic effects seem to be the most outstanding pharmacological
difference between MDPV and 4-MMC. This supports previous research evidence that 4-MMC
substituted for MDMA, a more potent serotonergic drug than other psychostimulants (Harvey
and Baker, 2016). Further investigation involving substitution tests with other serotonergic
substances is required to fully evaluate this proposition. Furthermore, dopaminergic mechanisms
may also be involved in the 4-MMC discriminative stimulus cue as evidenced by stimulus
generalization blockade when the D1 antagonist, Schering 39116, was given as a pretreatment
prior to 4-MMC substitution tests for the dopaminergic psychostimulant, d-amphetamine
(Harvey et al., 2017).
Ongoing investigation will further clarify the role of various neuroreceptors and their
subtypes in the discriminative stimulus effects of both 4-MMC and MDPV. At present, it may
be hypothesized that substances with predominantly dopaminergic activity, such as amphetamine
and methamphetamine, may substitute for MDPV while serotonergic substances, such as LSD
and MDMA, may substitute for 4-MMC. Such results would be consistent with prior research
(Berquist and Baker, 2017; Berquist et al., 2017; De Large, Erwin, and Winsaur, 2017; Harvey et
al., 2017; Harvey and Baker, 2016), but remain to be demonstrated by ongoing research.
Receptor specific antagonist tests would aid in determining the relative contributions of various
neuroreceptors to the discriminative stimulus effects of both 4-MMC and MDPV. These types of
tests may also be more well suited to answer the question of whether the differential
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discriminative stimulus effects of these two drugs rely on dopaminergic versus serotonergic
differences.
Also warranted are studies to investigate whether the optical isomers of 4-MMC and
MDPV have differential discriminative stimulus effects. A growing body of evidence suggests
that the reinforcing and rewarding properties of MDPV and 4-MMC may vary among their
enantiomers (Gannon et al., 2017; Philogene-Khalid et al., 2017). Determination of
discriminative stimulus effects may be crucial for the development of targeted therapeutics to
treat addiction to either 4-MMC or MDPV. Some evidence suggests that the S enantiomer of 4MMC reduces anxiety and depressant-like effects observed in cocaine and MDPV abstinent rats
(Philogene-Khalid, Hicks, Reitz, Liu-Chen, and Rawls, 2017). Thus, if 4-MMC isomers have
differential reinforcing properties, full or partial substitution for a racemic training dose may
indicate a potential target for therapeutic intervention. MDPV enantiomers would not likely be
ideal therapeutic targets as both the S and R enantiomers support high levels of drug selfadministration, although there are differences in potency (Gannon et al., 2017). Such a research
project would require characterization of toxicological effects associated with each isomer.
In conclusion, male Sprague-Dawley rats readily learned to discriminate 4-MMC and
MDPV from saline in a three-lever drug discrimination procedure. Although further
experimental confirmation is required, preliminary data indicate that serotonergic differences
may account, at least in part, for differential discriminative stimulus effects between these drugs.
Due to the relative speed with which animals acquired the discrimination in the present
experiment, the current research further supports a body of evidence that the three-lever drug
discrimination design is more sensitive than comparable two-lever discrimination designs in
detecting differences between pharmacologically similar substances.

23
REFERENCES
Aarde, S. M., Huang, P. K., Dickerson, T. J., & Taffe, M. A. (2015). Binge-like acquisition of
3,4-methylenedioxypyrovalerone (MDPV) self-administration and wheel activity in
rats. Psychopharmacology,232(11), 1867-1877.
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders
(5th ed.). Arlington, VA: American Psychiatric Publishing.
Banks, M. L., Worst, T. J., & Sprague, J. E. (2014). Synthetic cathinones and amphetamine
analogues: What’s the rave about? Journal of Emergency Medicine,46(5), 632-642.
Baron, M., Elie, M., & Elie, L. (2011). An analysis of legal highs-do they contain what it says on
the tin? Drug Testing and Analysis,3(9), 576-581.
Baumann, M. H., Ayestas, M. A., Jr., Partilla, J. S., Sink, J. R., Shulgin, A. T., Daley, P. F., . . .
Cozzi, N. V. (2012). The designer methcathinone analogs, mephedrone and methylone,
are substrates for monoamine transporters in brain
tissue. Neuropsychopharmacology, 37(5), 1192-1203.
Baumann, M. H., Partilla, J. S., Lehner, K. R., Thorndike, E. B., Hoffman, A. F., Holy, M., . . .
Schindler, C. W. (2013). Powerful cocaine-like actions of 3,4methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’
products. Neuropsychopharmacology,38(4), 552-562.
Berquist, M. D., & Baker, L. E. (2017). Characterization of the discriminative stimulus effects of
3,4-methylenedioxypyrovalerone in male Sprague-Dawley rats. Behavioural
Pharmacology,28(5), 394-400.
Berquist, M. D., Peet, M. M., & Baker, L. E. (2015). Behavioral sensitization following
concurrent exposure to mephedrone and D-amphetamine in female mice. Behavioural
Pharmacology,26, 180-183.
Berquist, M. D., Thompson, N. A., & Baker, L. E. (2017). Evaluation of training dose in male
Sprague-Dawley rats trained to discriminate 4-methylmethcathinone.
Psychopharmacology,234(21), 3271-3278.
Berquist, M. D., Traxler, H. K., Mahler, A. M., & Baker, L. E. (2016). Sensitization to the
locomotor stimulant effects of “bath salt” constituents, 4-methylmethcathinone (4-MMC)
and 3,4-methylenedioxypyrovalerone (MDPV), in male Sprague-Dawley rats. Drug and
Alcohol Dependence,164, 128-134.
Brain_Damage. "Not an MDMA Substitute: An Experience with MDPV
(exp110196)". Erowid.org. Mar 30, 2017. erowid.org/exp/110196

24
Busardo, F. P., Kyriakou, C., Napoletano, S., Marinelli, E., & Zaami, S. (2015). Mephedrone
related fatalities: A review. European Review for Medical and Pharmacological
Sciences,19, 3777-3790.
Callahan, P. M., & Appel, J. B. (1990). Differentiation between the stimulus effects of (+)lysergic acid diethylamide and lisuride using a three-choice, drug discrimination
procedure. Psychopharmacology,100(1), 13-18.
Cameron, K. N., Kolanos, R., Solis, E.,Jr, Glennon, R. A., & De Felice, L.,J. (2013a). Bath salts
components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at
the human dopamine transporter. British Journal of Pharmacology, 168(7), 1750-1757.
Cameron, K., Kolanos, R., Verkariya, R., De Felice, L., & Glennon, R. A. (2013b). Mephedrone
and methylenedioxypyrovalerone (MDPV), major constituents of "bath salts," produce
opposite effects at the human dopamine transporter.Psychopharmacology, 227(3), 493499.
Coppola, M., & Mondola, R. (2012). Synthetic cathinones: Chemistry, pharmacology and
toxicology of a new class of designer drugs of abuse marketed as “bath salts” or “plant
food”. Toxicology Letters,211, 144-149.
Creehan, K. M., Vandewater, S. A., & Taffe, M. A. (2015). Intravenous self-administration of
mephedrone, methylone and MDMA in female rats. Neuropharmacology,92, 90-97.
Delarge, A. F., Erwin, L. L., & Winsauer, P. J. (2017). Atypical binding at dopamine and
serotonin transporters contribute to the discriminative stimulus effects of
mephedrone. Neuropharmacology,119, 62-75.
Drug Enforcement Agency. (2016). National Drug Threat Assessment 2016. United States
Department of Justice.
European Monitoring Centre for Drugs and Drug Addiction (2017), European Drug Report
2017: Trends and Developments, Publications Office of the European Union,
Luxembourg.
Gannon, B. M., Rice, K. C., & Collins, G. T. (2017). Reinforcing effects of abused ‘bath salts’
constituents 3,4-methylenedioxypyrovalerone and α-pyrrolidinopentiophenone and their
enantiomers. Behavioural Pharmacology,28(7), 578-581.
Gannon, B. M., Russell, L. N., Modi, M. S., Rice, K. C., & Fantegrossi, W. E. (2017). Effects of
orally self-administered bath salt constituent 3,4-methylenedioxypyrovalerone (MDPV)
in mice. Drug and Alcohol Dependence,179, 408-415.
Gatch, M. B., Taylor, C. M., & Forster, M. J. (2013). Locomotor stimulant and discriminative
stimulus effects of ‘bath salt’ cathinones. Behavioural Pharmacology, 24(5-6), 437-447.

25
German, C. L., Fleckenstein, A. E., & Hanson, G. R. (2014). Bath salts and synthetic cathinones:
An emerging designer drug phenomenon. Life Sciences,97(1), 2-8.
GewaltHaber. "The Full Ride: An Experience with MDPV (exp90171)". Erowid.org. May
12, 2011. erowid.org/exp/90171
Glennon, R. A. (2014). Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging
illicit drugs that will need targeted therapeutic intervention. Emerging Targets &
Therapeutics in the Treatment of Psychostimulant Abuse Advances in Pharmacology,581620.
Goodwin, A. K., & Baker, L. E. (2000). A three-choice discrimination procedure dissociates the
discriminative stimulus effects of d-amphetamine and (±)-MDMA in rats. Experimental
and Clinical Psychopharmacology, 8(3), 415-423.
Gregg, R. A., Tallarida, C. S., Reitz, A., Mccurdy, C., & Rawls, S. M. (2013). Mephedrone (4methylmethcathinone), a principal constituent of psychoactive bath salts, produces
behavioral sensitization in rats. Drug and Alcohol Dependence,133(2), 746-750.
Gregg, R. A., Tallarida, C. S., Reitz, A. B., & Rawls, S. M. (2013). Mephedrone interactions
with cocaine: Prior exposure to ‘bath salt’ constituent enhances cocaine-induced
locomotor activation in rats. Behavioural Pharmacology,24(8), 684-688.
Hall, C., Heyd, C., Butler, C., & Yarema, M. (2014). ‘‘Bath salts’’ intoxication: A new
recreational drug that presents with a familiar toxidrome. Canadian Journal of
Emergency Medicine,16(2), 171-176.
Harmoniousaccord. "Rubbery Abandon: An Experience with 4-Methylmethcathinone
(exp78080)". Erowid.org. May 27, 2009. erowid.org/exp/78080
Harvey, E. L., & Baker, L. E. (2016). Differential effects of 3,4-methylenedioxypyrovalerone
(MDPV) and 4-methylmethcathinone (mephedrone) in rats trained to discriminate
MDMA or a d-amphetamine MDMA mixture. Psychopharmacology,233(4), 673-680.
Harvey, E. L., Burroughs, R. L., & Baker, L. E. (2017). Effects of D1 and D2 receptor
antagonists on the discriminative stimulus effects of methylendioxypyrovalerone and
mephedrone in male Sprague-Dawley rats trained to discriminate Damphetamine. Behavioural Pharmacology,28(7), 586-589.
Johnson, P. S., & Johnson, M. W. (2014). Investigation of “bath salts” use patterns within an
online sample of users in the United States. Journal of Psychoactive Drugs,46(5), 369378.
Johnston, L. D., Miech, R. A., O’Malley, P. M., Bachman, J. G., Schulenberg, J. E., & Patrick,
M. E. (2018). Monitoring the Future national survey results on drug use: 1975-2017:

26
Overview, key findings on adolescent drug use. Ann Arbor: Institute for Social Research,
The University of Michigan.
Jovialla. "Sparkle: An Experience with 4-Methylmethcathinone (Mephedrone)
(exp83324)". Erowid.org. Mar 28, 2010. erowid.org/exp/83324
Karlsson, L., Andersson, M., Kronstrand, R., & Kugelberg, F. C. (2014). Mephedrone,
Methylone and 3,4-Methylenedioxypyrovalerone (MDPV) Induce Conditioned Place
Preference in Mice. Basic & Clinical Pharmacology & Toxicology,115(5), 411-416.
King, H. E., Wakeford, A., Taylor, W., Wetzell, B., Rice, K. C., & Riley, A. L. (2015). Sex
differences in 3,4-methylenedioxypyrovalerone (MDPV)-induced taste avoidance and
place preferences. Pharmacology Biochemistry and Behavior,137, 16-22.
King, H. E., Wetzell, B., Rice, K., & Riley, A. (2015). An assessment of MDPV-induced place
preference in adult Sprague-Dawley rats. Drug and Alcohol Dependence,156.
Lisek, R., Xu, W., Yuvasheva, E., Chiu, Y., Reitz, A. B., Liu-Chen, L., & Rawls, S. M. (2012).
Mephedrone (‘bath salt’) elicits conditioned place preference and dopamine-sensitive
motor activation. Drug and Alcohol Dependence, 126(1-2), 257-262.
López-Arnau, R., Luján, M. A., Duart-Castells, L., Pubill, D., Camarasa, J., Valverde, O., &
Escubedo, E. (2017). Exposure of adolescent mice to 3,4-methylenedioxypyrovalerone
increases the psychostimulant, rewarding and reinforcing effects of cocaine in
adulthood. British Journal of Pharmacology,174(10), 1161-1173.
Motbey, C. P., Clemens, K. J., Apetz, N., Winstock, A. R., Ramsey, J., Li, K. M., . . . Mcgregor,
I. S. (2013). High levels of intravenous mephedrone (4-methylmethcathinone) selfadministration in rats: Neural consequences and comparison with
methamphetamine. Journal of Psychopharmacology,27(9), 823-836.
Nguyen, J. D., Grant, Y., Creehan, K. M., Vandewater, S. A., & Taffe, M. A. (2016). Escalation
of intravenous self-administration of methylone and mephedrone under extended access
conditions. Addiction Biology,22(5), 1160-1168.
Philogene-Khalid, H. L., Hicks, C., Reitz, A. B., Liu-Chen, L., & Rawls, S. M. (2017). Synthetic
cathinones and stereochemistry: S enantiomer of mephedrone reduces anxiety- and
depressant-like effects in cocaine- or MDPV-abstinent rats. Drug and Alcohol
Dependence,178, 119-125.
Philogene-Khalid, H. L., Simmons, S. J., Nayak, S., Martorana, R. M., Su, S. H., Caro, Y., . . .
Rawls, S. M. (2017). Stereoselective Differences between the Reinforcing and
Motivational Effects of Cathinone-Derived 4-Methylmethcathinone (Mephedrone) In
Self-Administering Rats. ACS Chemical Neuroscience,8(12), 2648-2654.

27
Schilmoeller, G. L., Schilmoeller, K. J., Etzel, B. C., & LeBlanc, J. M. (1979). Conditional
discrimination after errorless and trial-and-error training. Journal of the Experimental
Analysis of Behavior, 31(3), 405-420.
Seth, P., Scholl, L., Rudd, R. A., & Bacon, S. (2018). Overdose deaths involving opioids,
cocaine, and psychostimulants — United States, 2015–2016. MMWR. Morbidity and
Mortality Weekly Report,67(12), 349-358.
Shanks, K. G., Dahn, T., Behonick, G., & Terrell, A. (2012). Analysis of first and second
generation legal highs for synthetic cannabinoids and synthetic stimulants by ultraperformance liquid chromatography and time of flight mass spectrometry. Journal of
Analytical Toxicology,36(6), 360-371.
Simmons, S. J., Gregg, R. A., Tran, F. H., Mo, L., Weltin, E. V., Barker, D. J., . . . Muschamp, J.
W. (2016). Comparing rewarding and reinforcing properties between ‘bath salt’ 3,4methylenedioxypyrovalerone (MDPV) and cocaine using ultrasonic vocalizations in
rats. Addiction Biology,23(1), 102-110.
Smushy. "Wasting a Night on Unknown Chemicals: An Experience with 4Methylmethcathinone (Mephedrone) (exp81410)". Erowid.org. Mar 26, 2010.
Substance Use and Mental Health Services Administration. (2014). Substance use disorders.
Retrieved June 25, 2018, from https://www.samhsa.gov/disorders/substance-use
United States Department of Justice. (2011). The economic impact of illicit drug use on
American society. National Drug Intelligence Center.
Varner K, Daigle K, Weed P, Lewis P, Mahne S, Sankaranarayanan A, Winsauer P (2013)
Comparison of the behavioral and cardiovascular effects of mephedrone with other drugs
of abuse in rats. Psychopharmacology 225, 675–685.
Watterson, L. R., Kufahl, P. R., Nemirovsky, N. E., Sewalia, K., Grabenauer, M., Thomas, B. F.,
. . . Olive, M. F. (2012). Potent rewarding and reinforcing effects of the synthetic
cathinone 3,4-methylenedioxypyrovalerone (MDPV). Addiction Biology,19(2), 165-174.
Winstock, A. R., Mitcheson, L. R., Deluca, P., Davey, Z., Corazza, O., & Schifano, F. (2010).
Mephedrone, new kid for the chop? Addiction,106(1), 154-161.
Winstock, A., Mitcheson, L., Ramsey, J., Davies, S., Puchnarewicz, M., & Marsden, J. (2011).
Mephedrone: Use, subjective effects and health risks. Addiction,106(11), 1991-1996.
Wright, T. H., Cline-Parhamovich, K., Lajoie, D., Parsons, L., Dunn, M., & Ferslew, K. E.
(2013). Deaths involving methylenedioxypyrovalerone (MDPV) in upper east
Tennessee. Journal of Forensic Sciences, 58(6), 1558.

28
APPENDIX

